US FDA: Drug makers mostly on time with postmarketing studies
This article was originally published in Scrip
Executive Summary
Most drug and biologic makers required to conduct postmarketing studies met their commitments in fiscal year 2011 of completing studies on time or progressing on schedule, the US FDA reported.